Cargando…
A rare compound heterozygous EIF2AK4 mutation in pulmonary veno-occlusive disease
BACKGROUND: Pulmonary veno-occlusive disease (PVOD) is a rare, progressive, and oft-fatal condition of pulmonary arterial hypertension that is typically difficult to diagnose and treat. However, with the development of next-generation sequencing technology, an increasing number of patients with PVOD...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710057/ https://www.ncbi.nlm.nih.gov/pubmed/36451176 http://dx.doi.org/10.1186/s12890-022-02256-9 |
_version_ | 1784841289649356800 |
---|---|
author | Zhang, Chun Du, Qiang Wang, Sha Zhang, Ruifeng |
author_facet | Zhang, Chun Du, Qiang Wang, Sha Zhang, Ruifeng |
author_sort | Zhang, Chun |
collection | PubMed |
description | BACKGROUND: Pulmonary veno-occlusive disease (PVOD) is a rare, progressive, and oft-fatal condition of pulmonary arterial hypertension that is typically difficult to diagnose and treat. However, with the development of next-generation sequencing technology, an increasing number of patients with PVOD are being diagnosed. METHODS: Initially, we used whole exome sequencing (WES) to identify the proband as a rare compound heterozygous mutation of EIF2AK4 in PVOD. Subsequently, the parents of patient underwent EIF2AK4 screening by Sanger sequencing. RESULTS: In this study, we describe the family tree of a patient with PVOD with a rare compound heterozygous EIF2AK4 mutation. Moreover, we identified a new EIF2AK4 mutation, c.2236_2237insAAGTCCTTCT, in exon 12 of the proband and his mother. This frameshift mutation led to premature termination of the coding protein sequence and widespread loss of protein function, which promoted the development of PVOD. CONCLUSIONS: Our results expand our understanding of the EIF2AK4 mutation spectrum in patients with PVOD, as well as highlight the clinical applicability of WES. |
format | Online Article Text |
id | pubmed-9710057 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-97100572022-12-01 A rare compound heterozygous EIF2AK4 mutation in pulmonary veno-occlusive disease Zhang, Chun Du, Qiang Wang, Sha Zhang, Ruifeng BMC Pulm Med Research Article BACKGROUND: Pulmonary veno-occlusive disease (PVOD) is a rare, progressive, and oft-fatal condition of pulmonary arterial hypertension that is typically difficult to diagnose and treat. However, with the development of next-generation sequencing technology, an increasing number of patients with PVOD are being diagnosed. METHODS: Initially, we used whole exome sequencing (WES) to identify the proband as a rare compound heterozygous mutation of EIF2AK4 in PVOD. Subsequently, the parents of patient underwent EIF2AK4 screening by Sanger sequencing. RESULTS: In this study, we describe the family tree of a patient with PVOD with a rare compound heterozygous EIF2AK4 mutation. Moreover, we identified a new EIF2AK4 mutation, c.2236_2237insAAGTCCTTCT, in exon 12 of the proband and his mother. This frameshift mutation led to premature termination of the coding protein sequence and widespread loss of protein function, which promoted the development of PVOD. CONCLUSIONS: Our results expand our understanding of the EIF2AK4 mutation spectrum in patients with PVOD, as well as highlight the clinical applicability of WES. BioMed Central 2022-11-30 /pmc/articles/PMC9710057/ /pubmed/36451176 http://dx.doi.org/10.1186/s12890-022-02256-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Zhang, Chun Du, Qiang Wang, Sha Zhang, Ruifeng A rare compound heterozygous EIF2AK4 mutation in pulmonary veno-occlusive disease |
title | A rare compound heterozygous EIF2AK4 mutation in pulmonary veno-occlusive disease |
title_full | A rare compound heterozygous EIF2AK4 mutation in pulmonary veno-occlusive disease |
title_fullStr | A rare compound heterozygous EIF2AK4 mutation in pulmonary veno-occlusive disease |
title_full_unstemmed | A rare compound heterozygous EIF2AK4 mutation in pulmonary veno-occlusive disease |
title_short | A rare compound heterozygous EIF2AK4 mutation in pulmonary veno-occlusive disease |
title_sort | rare compound heterozygous eif2ak4 mutation in pulmonary veno-occlusive disease |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710057/ https://www.ncbi.nlm.nih.gov/pubmed/36451176 http://dx.doi.org/10.1186/s12890-022-02256-9 |
work_keys_str_mv | AT zhangchun ararecompoundheterozygouseif2ak4mutationinpulmonaryvenoocclusivedisease AT duqiang ararecompoundheterozygouseif2ak4mutationinpulmonaryvenoocclusivedisease AT wangsha ararecompoundheterozygouseif2ak4mutationinpulmonaryvenoocclusivedisease AT zhangruifeng ararecompoundheterozygouseif2ak4mutationinpulmonaryvenoocclusivedisease AT zhangchun rarecompoundheterozygouseif2ak4mutationinpulmonaryvenoocclusivedisease AT duqiang rarecompoundheterozygouseif2ak4mutationinpulmonaryvenoocclusivedisease AT wangsha rarecompoundheterozygouseif2ak4mutationinpulmonaryvenoocclusivedisease AT zhangruifeng rarecompoundheterozygouseif2ak4mutationinpulmonaryvenoocclusivedisease |